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RESUMO – A psoríase é uma doença inflamatória crónica da pele, imunomediada, potencialmente desfigurante e incapacitan-
te, que afeta mundialmente mais de 100 milhões de indivíduos. A combinação fixa de calcipotriol e betametasona (0,005% Cal/ 
0,064% BD) é o tratamento tópico recomendado. No entanto, os tratamentos tópicos estão associados a falta de eficácia e baixa 
adesão, nomeadamente devido às fracas propriedades cosméticas das formulações disponíveis. Para melhorar a aceitação e a 
adesão dos doentes, foi desenvolvida uma espuma cutânea de Cal/ BD para tratamento de adultos com psoríase. Os ensaios clí-
nicos de fase II e III mostraram que a formulação fixa dos dois compostos é consistentemente mais eficaz e mais segura do que os 
ingredientes individuais, considerando o mesmo veículo. A espuma cutânea demonstrou maior eficácia em estudos clínicos, sendo 
que uma análise conjunta dos principais estudos mostrou que isso não ocorre à custa do perfil de segurança. Além disso, a espuma 
cutânea Cal/ BD mostrou uma melhoria significativa da eficácia em comparação com pomadas, géis e loções. O perfil de eficácia 
e segurança melhorado desta nova formulação, maior tolerabilidade e resposta mais rápida, aliados a uma menor frequência de 
tratamento (1x por dia), oferece maior conveniência e melhor aceitação do que as respetivas monoterapias (2x por dia) podendo, 
eventualmente, melhorar a adesão ao tratamento, conduzindo a melhorias mais significativas na qualidade de vida dos doentes, 
representando uma opção terapêutica mais vantajosa para os doentes. São necessários mais estudos para explorar a possibilidade 
desta espuma cutânea permitir a gestão da doença a longo prazo.
PALAVRAS-CHAVE – Aerossóis; Betametasona/administração e dosagem; Betametasona/antagonistas & inibidores; Calcitriol/
administração & dosagem;  Calcitriol/antagonistas & inibidores; Gel; Psoríase/tratamento. 
New Calcipotriol/Betamethasone Dipropionate  
Foam Formulation for the Treatment of Psoriasis:  
An Overview  
ABSTRACT – Psoriasis is a chronic, inflammatory, immune-mediated, potentially disfiguring and disabling skin disorder, affecting 
over 100 million individuals worldwide. Calcipotriol plus betamethasone fixed-combination (0.005% Cal/0.064% BD) is the recom-
mended topical treatment for psoriasis. However, topical treatments are associated to lack of efficacy and low adhesion rates due 
to poor cosmetic characteristics’ formulations, and vehicle issues. To answer the need for improving patients’ acceptability and 
adherence, an innovative Cal/BD aerosol foam formulation was developed for the topical treatment of adults with plaque psoria-
sis. Phase II and III clinical trials have consistently shown that the two-compound formulation is more effective and safer than its 
individual ingredients in the same vehicle. Cal/BD aerosol foam formulation has proved higher efficacy in clinical studies, and a 
pooled analysis of the main clinical studies has demonstrated that this does not occur at the safety profile expense. Furthermore, 
Cal/BD aerosol foam has shown a significantly improved efficacy compared with more traditional formulations, such as ointments, 
gels, and lotions. The improved efficacy and safety profile of this new formulation, together with the once-daily treatment, a more 
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INTRODUCTION
Psoriasis is a chronic, inflammatory, immune-mediated, 
potentially disfiguring and disabling skin disorder that affects 
over 100 million individuals worldwide (≈ 2% of the world’s 
population). It affects men and women of all ages, regardless 
of ethnic origin.1
With higher rates in developed countries,1-2 evidence su-
ggests that psoriasis’ prevalence may be increasing.3 Publi-
shed data on the prevalence of psoriasis vary between 0.09% 
and 11.4%.5,4 In Portugal psoriasis prevalence ranges between 
1% and 2%, affecting about 200 000 to 250 000 individuals.5-6
Plaque psoriasis (or psoriasis vulgaris) is the most common 
type (70% – 90% of cases), although it can also present as 
erythrodermic, guttate, inverse, nail, or pustular forms.2-4 Pso-
riasis may have extracutaneous involvement (e.g. ophthalmic 
symptoms, psoriatic arthritis) and an increased risk of comor-
bidities (e.g. cardiovascular disease, malignancy, metabolic 
syndrome).3,7,8
Clinical manifestations include well-defined, erythema-
tous plaques, covered in silvery-white scales, and common 
symptoms include itching and pain.3,4 Many studies have de-
monstrated that even in patients with mild-to-moderate di-
sease or even with a relatively limited body surface area (BSA) 
affected, the visible and highly stigmatizing nature of psoria-
sis can substantially impact patients’ health-related quality of 
life (HR-QoL).1,2,9
As a chronic-relapsing disease, psoriasis requires long-
-term treatment. The selection of proper treatment is guided 
by patient-specific presentation (disease extent and severity), 
history of past treatments’ response, patients’ preference, and 
clinicians’ judgment, aiming to optimize disease control and 
long-term management.10-11
1. STATE OF THE ART ON PSORIASIS TREATMENT
Therapeutic options include topical, photo and systemic 
therapy. Each treatment presents limitations: poor efficacy/ 
tolerability ratio, drug interactions, patients’ comorbidities, 
administration route, regimen inconvenience (e.g. time consu-
ming or frequent application), high costs, which are the main 
reasons for non-adherence, consequently leading to an un-
successful disease management.3,16
Systemic therapy (either using traditional agents, e.g. me-
thotrexate, cyclosporine and acitretin, or biological’s, e.g. 
anti-TNFa, anti-IL12/23 and anti-IL17 agents) is the corners-
tone for moderate-to-severe psoriasis treatment.13,16-12 Photo-
therapy or topical treatments are recommended for mild or 
mild-to-moderate disease, which affects most patients (≈70-
80%).2,12, 13,14  
Current research is mainly focused on biologic or syste-
mic treatment agents disregarding topicals, which have had 
few developments in recent years.2,12,15,16 Nevertheless, the re-
commended topical treatment for psoriasis includes the use of 
vitamin D analogues and corticosteroids, either separate or 
as a fixed-combination.13,15,19,17 A well-established fixed-dose 
combination of a synthetic vitamin D3 analogue (calcipotriol/
calcipotriene) and a synthetic corticosteroid (betamethasone 
dipropionate) (0.005% Cal/0.064% BD) is the most frequen-
tly used combination product for topical treatment of plaque 
psoriasis in adults, either in ointment or gel formulations, in 
Europe and in USA.1,18-19  
However, topical treatment is associated to lack of effica-
cy and success and low adhesion rates due to formulations 
with poor cosmetic characteristics, and vehicle issues, often 
reported as greasy, oily, and sticky.3 But, even though there 
are no new compounds available, new topical formulations 
could help to overcome topical treatment-related challenges, 
leading to a better treatment acceptability and adherence im-
provement, helping to provide subsequent long-term mainte-
nance of a disease-free state.13
Besides patients’ adhesion rates, topical therapy’s efficacy 
is also correlated with the skin penetration of the active in-
gredients. One method to augment skin penetration’s rate 
is to increase the active ingredients’ concentration beyond 
the normal solubility limit, to develop a stable and supersa-
turated formulation,13 enhancing the thermodynamic activity 
of the drug.27 To answer the need for improving patients’ 
acceptability and adherence, an innovative Cal/BD formula-
tion was developed, and an alcohol-free aerosol foam was 
approved for the once daily topical treatment of plaque pso-
riasis in adults by FDA in October 2015 and EMA in March 
2016.3,22-25,20
This review article pretends to give an overview of a new 
calcipotriol plus betamethasone dipropionate (Cal/BD) for-
mulation for the topical treatment of adults with plaque pso-
riasis.
2. CAL/BD AEROSOL FOAM PHARMACOLOGICAL 
PROFILE
Cal/BD aerosol foam belongs to the pharmacotherapeutic 
group of antipsoriatics for topical use.21 With an innovative 
and renewed formulation, it is a liquid supplied in a pressu-
rized spray can containing a vehicle-based calcipotriol and 
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acceptable tolerability profile, and an early and rapid response, offers improved convenience and better acceptance over the twice-
-daily applications required for the respective monotherapies, which may improve adherence to treatment, leading to faster and 
greater improvements in HR-QoL, representing a useful therapeutic option to the management of patients with plaque psoriasis. 
Further clinical investigations to explore the possibility of Cal/BD aerosol foam treatment ability to provide long-term psoriasis’ ma-
nagement are required.
KEYWORDS – Aerosols; Betamethasone/administration & dosage; Betamethasone/analogs & derivatives; Calcitriol/administration 
& dosage; Calcitriol/analogs & derivatives; Psoriasis/drug therapy.
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betamethasone dipropionate dissolved in a mixture of volatile 
propellants, butane and dimethyl ether. When the formulation 
is sprayed, the propellants evaporate rapidly, and a thin layer 
of foam forms on the skin.22 Cal/BD aerosol foam should be 
applied topically to the affected areas once daily for a ma-
ximum of 4 weeks, not exceeding 15 g daily or 60g every 4 
days.26,27,23 
Clinical and pharmacological effects of the two acti-
ve agents are well known, and its action mechanism in pla-
que psoriasis has been approached by several authors.2,3,26 
Treatment goal is to clear the psoriatic plaques by inhibiting 
the underlying inflammation and normalizing skin homeos-
tasis, keratinocyte proliferation and differentiation, and to 
provide immunomodulation.13 In combination, calcipotriol 
and betamethasone promote greater anti-inflammatory and 
anti-proliferative effects than either component alone.2,27 Its 
complementary anti-inflammatory and immunomodulatory 
effects lead to the disruption of the inflammatory loop reac-
tion underlying psoriasis pathogenesis.13
2.1. Pharmacodynamic properties
A prospective, multicentre, single-group, open-label study 
was conducted under maximal use conditions in 35 adults 
with extensive psoriasis. Aiming to evaluate the effect of Cal/
BD aerosol foam on hypothalamic–pituitary–adrenal (HPA) 
axis suppression and calcium metabolism, the foam was ap-
plied once daily on the affected areas for up to 4 weeks, mean 
weekly dose of 61.8 g. Adrenal response to adrenocortico-
tropic hormone (ACTH) was determined by measuring serum 
cortisol levels. Hormonal stimulation and serum and urine cal-
cium assessments occurred at baseline and at 4 weeks. None 
of the patients had suppressed serum cortisol levels nor eleva-
ted serum or urine calcium levels.27
2.2. Pharmacokinetic properties
The extent of percutaneous absorption of the two acti-
ve ingredients following topical application was determined 
in the above-mentioned trial that also aimed to assess the 
pharmacokinetic profile of the active ingredients and its main 
metabolites. Plasma concentrations were assessed at baseli-
ne and at week 4. Following systemic exposure, both active 
ingredients are rapidly and extensively metabolised. In most 
patients’ samples, plasma concentrations of calcipotriol and 
betamethasone dipropionate and its metabolites were below 
the quantification’s lower limit.26,27 These results are consistent 
with those of tissue distribution’s studies in rats administered 
with radiolabelled calcipotriol and betamethasone dipropio-
nate, that showed that the kidney and liver had the highest 
radioactivity level.27
In vitro skin penetration and ex vivo biomarker assays were 
conducted to compare the skin penetration and bioavailabi-
lity of Cal and BD from the aerosol foam and ointment for-
mulations, respectively. Cal/BD foam applied to in vitro skin 
is maintained for at least 26 hours, which may explain the 
bioavailability increase of Cal/BD aerosol foam versus other 
formulations.31
3. CAL/BD AEROSOL EFFICACY AND SAFETY
3.1. Efficacy data
3.1.1. Preclinical data/ Phase I
A nonclinical, in vitro, skin-penetration study24,25 was de-
veloped to establish Cal/BD aerosol foam efficacy versus 
ointment. This skin-penetration model has demonstrated 
enhanced drug delivery, whereby steady-state Cal/BD levels 
were significantly higher following aerosol foam applica-
tion compared with ointment. This led to significantly more 
rapid absorption and higher concentration of calcipotriol (p < 
0.001) and betamethasone dipropionate (p = 0.002) within 
the skin samples (Table 1).
In a Phase I (NCT01946386) study, 35 healthy volunteers 
received a single application of Cal/BD aerosol foam, clobe-
tasol propionate (CP) cream, Cal/BD ointment, fluocinolone 
acetonide (FA) ointment and betamethasone dipropionate ae-
rosol foam.34,26 Skin blanching was measured to evaluate va-
soconstrictor potential as a surrogate of steroid potency. Cal/
BD aerosol foam proved greater vasoconstriction than Cal/
BD and FA ointment, but less vasoconstriction than CP cream 
(Table 1).
3.1.2. Phase II
In a Phase IIa (NCT01347255), 4-week, investigator-blin-
ded study involving 24 patients with psoriasis vulgaris, the an-
tipsoriatic effect of Cal/BD foam was measured by assessing 
the decrease in mean Total Clinical Score (TCS; the sum of 
erythema, scaling and lesional thickness scores).34,27 Cal/BD 
foam led to a greater decrease in TCS compared with Cal/
BD ointment (–6.0 vs –5.3; p = 0.038), betamethasone di-
propionate foam (–6.0 vs –5.0; p = 0.005) and foam vehicle 
(–6.0 vs –1.9; p < 0.001). Ultrasound measurements showed 
that reductions in total skin thickness and dermis inflammation 
psoriasis-associated were consistently greater with Cal/BD ae-
rosol foam than with all other treatments (Table 1).
Cal/BD aerosol foam’s systemic safety was assessed in a 
phase II (NCT01600222) multicentre, single-arm, open-label, 
maximal-use systemic-exposure trial.28 Cal/BD foam once 
daily was applied to adult patients with moderate to severe, 
extensive psoriasis. Endpoints were week 4 abnormal adre-
nocorticotropic hormone (ACTH) challenge test and change 
in albumin-corrected serum calcium, 24-hour urinary calcium 
excretion, and urinary calcium-creatinine ratio. At week 4, all 
35 patients exhibited normal ACTH responses and changes in 
calcium homeostasis were minor and not clinically relevant. 
No patients experienced elevations above normal. Disease se-
verity generally improved, and 49% of patients achieved treat-
ment success according to the Physician’s Global Assessment 
of Disease Severity (Table 1).
In 376 patients with psoriasis vulgaris enrolled in a phase II 
(NCT01536886), multicentre, investigator-blind, randomized, 
4-week trial, significantly more patients using Cal/BD aerosol 
foam achieved treatment success at week 4 versus Cal/BD 
ointment (54.6 vs 43.0%; p = 0.025).34,29 Mean mPASI score 
was significantly improved for aerosol foam versus ointment 
by week 1 (mean difference –0.7, p = 0.001) and maintained 
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Table 1 - Efficacy and safety results from Cal/BD clinical trials. 
Clinical 
Trial
Study design Study population
Treatments & 
formulations
Endpoints/ 
Outcomes
Efficacy results Safety results
Phase I
Queille-Roussel, 
201635
NCT01946386
Phase I, single-centre, 
investigator-blinded, 
vehicle-controlled, intra-
individual comparison 
vasoconstriction study.
35 healthy volunteers 
from 18-50 y, skin type I 
to IV (Fitzpatrick scale).
Single application on 
selected sites: Cal/
BD aerosol foam, 
clobetasol propionate 
0.5 mg/g cream (CP; 
very potent), Cal/
BD ointment (potent), 
fluocinolone acetonide 
0.25 mg/g ointment 
(FA; moderately potent), 
BD aerosol foam and 
aerosol foam vehicle. A 
7th untreated site acted 
as a negative control.
Skin blanching was 
assessed by visual (pri-
mary response criterion) 
and colorimetric a* 
and L* measurements 
(secondary criteria), and 
was analysed over time 
(6-32 h post-applica-
tion).
All active treatments led 
to significantly greater 
skin blanching than 
control. By visual assess-
ment, skin blanching 
with Cal/BD aerosol 
foam was significantly 
less compared with CP 
cream [mean AUC0-32 
2560 vs 3831; mean 
difference=-1272; 95% 
confidence interval 
(CI): -1598, -945; p < 
0.001], similar to BD 
aerosol foam (mean 
AUC0-32 2560 vs. 
2595; mean differ-
ence=-35; 95% CI: 
-362, 292; p=0.83) 
and significantly greater 
than Cal/BD ointment 
(mean AUC0-32 2560 
vs 2008; mean differ-
ence=552; 95% CI: 
225, 878; p=0.001) 
and FA ointment (mean 
AUC0-32 2560 vs 
1981; mean differ-
ence=578; 95% CI: 
251, 905; p <0.001). 
Colorimetric assess-
ments a* and L* also 
indicated significantly 
reduced skin blanching 
with Cal/BD aerosol 
foam compared with CP 
cream.
Throughout the study, 
there were no reports of 
AEs, serious AEs
or ADRs, no clinically 
relevant changes in pa-
tient vital signs and
no withdrawals due 
to AEs.
Throughout the study, 
there were no reports 
of AEs, serious AEs or 
ADRs, no clinically rel-
evant changes in patient 
vital signs and no with-
drawals due to AEs.
Queille-Roussel, 
201540 
NCT01935869
Single-centre, ran-
domized, investigator-
blind, phase I study.
213 healthy volun-
teers, median age 
44y (range 19-65) 
randomized to 3 test 
sites.
5 applications/ prod-
uct/ week of Cal/BD 
foam, foam vehicle 
and white petrolatum 
(negative control), 
under semi occlusive 
conditions (patches) 
for 3 weeks (induction 
phase), then 1 ap-
plication (challenge 
phase), following a 
2-week rest period.
Induction phase - skin 
irritation analysis: 
MDR and MCII.
Challenge phase 
- skin sensitization 
analysis: number 
of volunteers with 
positive sensitiza-
tion at the end of 
dermal response was 
assessed by a 6-point 
scale (0, 0.5, 1, 2, 
3, 4) 30’ after patch 
removal in induction 
phase, and by a 
5-point scale (ranging 
from ‘no reaction’ 
to ‘extreme positive 
reaction’) at 3 time 
points up to 72h after 
the single application 
in challenge phase. 
Following challenge 
phase, a certified der-
matologist considered 
whether sensitization 
reactions occurred at 
any test site, with the 
scale: 0 ¼ negative, 
1 ¼ equivocal, 3 ¼ 
positive.
During the induction 
phase, MDR=0 (no 
response) or 0.5 
(questionable or faint, 
indistinct erythema) 
was reported for 79% 
of volunteers for Cal/
BD foam treated sites 
vs 98% for vehicle and 
control. The highest 
score was 2 (erythema 
with slight-moderate 
oedema) reported 
in 3 volunteers, 
all following Cal/
BD foam applica-
tion. MCII (induction 
phase) was low for all 
treatments: Cal/BD 
foam, 0.10; vehicle, 
0.02; control, 0.02; 
comparative analysis 
of Cal/BD foam vs 
control was statistically 
significant different 
(95% CI 0.07, 0.10; 
p =0.001). There was 
no indication of any 
equivocal/ positive 
sensitization reactions.
Adverse drug 
reactions were 
experienced by 22 
volunteers.
Cal/BD foam: follicu-
litis, n ¼ 20; pruritus, 
n ¼ 8
Vehicle: urticaria, n 
¼ 2; skin irritation, 
n ¼ 1.
ACTH - Adrenocorticotropic hormone; ADRs – Adverse reactions; AEs – Adverse events; AUC – Area under the curve; DLQI - Dermatology Life-Quality Index; DTT 
– Difficult to treat; HR-QOL – Health-related quality of life; MDR - maximal dermal response; MCII - mean cumulative irritation index; mPASI – modified psoriasis 
area and severity index; pts – Patients; SAES – Serious adverse events; SD – Standard deviation; TCS - Total clinical score; y - Years
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Table 1 (Cont.) - Efficacy and safety results from Cal/BD clinical trials. 
Clinical 
Trial
Study design Study population
Treatments & 
formulations
Endpoints/ 
Outcomes
Efficacy results Safety results
Phase II
Queille-Roussel, 
201536
NCT01347255
Phase IIa, single-centre, 
investigator-blinded, 
exploratory study, with 
intra-individual compar-
ison using a modified 
psoriasis plaque test.
24 patients, median age 
52.5y (range 21-75).
Cal/BD foam, Cal/BD 
ointment, BD foam and 
Cal/BD foam vehicle 
once daily (6 days/
week) for 4 weeks, 
randomized to 4 plaque 
test sites (5 cm2 each).
Primary efficacy 
endpoint: change in 
TCS (sum of erythema, 
scaling and lesional 
thickness). 
Secondary endpoints: 
ultrasonographic chang-
es in total skin thickness 
and echo-poor band 
thickness, and adverse 
events.
At week 4, test sites 
treated with Cal/BD 
foam had a signifi-
cantly greater decrease 
in mean (±SD) TCS 
(-6.00 ± 1.27) vs 
those treated with Cal/
BD ointment (-5.25 
± 1.78; difference 
-0.75; 95 % CI -1.46 to 
-0.04; p=0.038), BD 
foam (-4.96 ± 1.85; 
difference -1.04; 95 
% CI -1.75 to -0.33; 
p=0.005) or foam 
vehicle (-1.88 ± 1.12; 
difference -4.13; 95 
% CI -4.83 to -3.42; 
p<0.001). Total skin 
thickness and echo-
poor band thickness of 
Cal/BD foam-treated 
sites were reduced to 
a greater extent than 
those treated with com-
parators.
Eleven patients reported 
17 adverse events, the 
most frequent being 
headache (five patients). 
There were no lesional/ 
perilesional AEs or 
adverse drug-related 
events.
Taraska, 
201637
NCT01600222
Phase II, multicentre, 
single-arm, open-
label, maximal-use 
systemic-exposure 
trial.
37 adult patients 
(mean age 48y; 46% 
female) with moderate 
to severe, extensive 
psoriasis (15%-30% 
of body surface area, 
including ≥30% of 
scalp).
Cal/BD foam once 
daily.
Endpoints were week 
4 abnormal ACTH 
challenge test and 
change in albumin-
corrected serum cal-
cium, 24-hour urinary 
calcium excretion, 
and urinary calcium-
creatinine ratio.
35 patients reaching 
week 4 exhibited nor-
mal ACTH responses. 
At week 4, changes in 
calcium homeostasis 
were minor and not 
clinically relevant; no 
patients experienced 
elevations above nor-
mal. Disease severity 
generally improved, 
and 49% of patients 
achieved treatment 
success according to 
the Physician's Global 
Assessment of Disease 
Severity.
Safety analysis set 
included 37 patients. 
Four patients (11%) 
reported 6 AEs of 
mostly mild or moder-
ate intensity, and 
no specific AE was 
experienced by more 
than 1 patient. One 
of the events, severe 
erythema, which oc-
curred within 4 days 
of treatment, was 
considered related to 
treatment. The other 5 
AEs were considered 
not related to treat-
ment. There were no 
clinically significant 
changes in hemato-
logic, biochemical, or 
urinalysis parameters.
Koo, 
201638
NCT01536886
Phase II, multicentre, 
investigator-blind, 
4-week trial.
376 adult patients 
with psoriasis were 
randomized.
Cal/BD aerosol foam 
(141 pts), Cal/BD 
ointment (135 pts), 
aerosol foam vehicle 
(49 pts) or ointment 
vehicle (51 pts) 
(3:3:1:1).
Primary efficacy 
endpoint: proportion 
of patients at week 4 
who achieved treat-
ment success (clear 
or almost clear with 
at least a two-step 
improvement) accord-
ing to the physician's 
global assessment of 
disease severity.
54.6% patients using 
Cal/BD aerosol foam 
achieved treatment 
success vs. 43.0% 
ointment (p=0.025); 
mean mPASI score 
was significantly dif-
ferent between Cal/
BD aerosol foam 
and Cal/BD ointment 
(mean difference -0.6; 
p=0.005). Rapid, 
continuous itch relief 
occurred with both 
active treatments.
One adverse drug 
reaction was reported 
with Cal/BD aerosol 
foam (application site 
itch).
ACTH - Adrenocorticotropic hormone; ADRs – Adverse reactions; AEs – Adverse events; AUC – Area under the curve; DLQI - Dermatology Life-Quality Index; DTT 
– Difficult to treat; HR-QOL – Health-related quality of life; MDR - maximal dermal response; MCII - mean cumulative irritation index; mPASI – modified psoriasis 
area and severity index; pts – Patients; SAES – Serious adverse events; SD – Standard deviation; TCS - Total clinical score; y - Years
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at week 4 (mean difference – 0.6, p = 0.005). Both active 
treatments led to rapid and marked itch relief within the first 
week and maintained throughout the study. Itch severity, mea-
sured using a visual analogue scale (VAS), decreased from 
52.7 to 13.5 at baseline and at week 4, respectively, in pa-
tients using Cal/BD aerosol foam, and from 52.1 to 14.5 in 
ointment-treated patients. Combination foam treatment was 
considered more effective and with the same tolerability as 
ointment (Table 1).
A phase II (NCT01536938), randomized, double-blind, 
multicentre, three-arm study enrolled 302 patients, rando-
mized to receive Cal/BD foam, Cal foam, or BD foam once 
daily for 4 weeks.30 Endpoints included treatment success of 
the body and scalp. At the end of the study, 45% of Cal/BD 
foam patients achieved treatment success, significantly more 
than Cal or BD foam (14.9%; OR 4.34 [95%CI 2.16,8.72] p 
< 0.001) (30.7%; 1.81 [1.00,3.26] p = 0.047). Mean mPASI 
score improved in all groups, with statistically significant diffe-
rences in week 4 Cal/BD foam score (2.37) versus Cal foam 
(4.39; mean difference -2.03 [-2.63] [-1.43] p < 0.001) and 
BD foam (3.37; -1.19 [-1.80] [-0.59] p < 0.001) (Table 1).
Aiming to compare the efficacy of Cal/BD foam with be-
tamethasone 17-valerate 2.25 mg (BV)-medicated plasters 
(recommended for treating psoriasis plaques localized in 
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Table 1 (Cont.) - Efficacy and safety results from Cal/BD clinical trials. 
Clinical 
Trial
Study design Study population
Treatments & 
formulations
Endpoints/ 
Outcomes
Efficacy results Safety results
Phase II
Lebwohl, 
201639
NCT01536938
Randomized, Double-
blind, Multicentre, 
Three-arm, Phase II 
Study.
302 patients (≥18 
years) with psoriasis 
vulgaris (≥mild disease 
severity by physicians’ 
global assessment).
Most patients (76%) 
had moderate psoriasis 
of the body (66% for 
scalp).
Patients were random-
ized (100:101:101) to 
receive Cal/BD foam, 
Cal foam, or BD foam 
once daily for 4 weeks.
Treatment success of the 
body ("clear"/"almost 
clear" from baseline 
moderate/severe 
disease; "clear" from 
baseline mild disease). 
Involved scalp treatment 
success was an ad-
ditional endpoint.
At week 4, 45% of 
Cal/BD foam patients 
achieved treatment suc-
cess, significantly more 
than Cal foam (14.9%; 
OR 4.34 [95%CI 
2.16,8.72] p<0.001) or 
BD foam (30.7%; 1.81 
[1.00,3.26] p=0.047). 
Mean mPASI (population 
baseline 7.6) improved 
in all groups, with 
statistically significant 
differences in Cal/BD 
foam score (2.37) vs 
Cal foam (4.39; mean 
difference -2.03 [-2.63] 
[-1.43] p<0.001) 
and BD foam (3.37; 
-1.19 [-1.80] [-0.59] 
p<0.001).
Four (Cal/BD), 10 (Cal), 
and 8 (BD) adverse drug 
reactions were reported.
Queille-Roussel, 
201740
NCT02518048
Phase IIa, random-
ized, single-centre, 
investigator-blinded, 
4-week study.
35 adult patients 
with psoriasis were 
included.
Cal/BD foam and 
BV-medicated plaster 
were applied once 
daily to 6 test sites 
(3 for each treatment).
The primary efficacy 
endpoint was absolute 
change in total clinical 
score (TCS; sum of 
erythema, scaling, 
and infiltration); 
secondary endpoints 
were changes from 
baseline in each indi-
vidual clinical score, 
ultrasonographic 
changes (total skin 
and echo-poor band 
thickness), and safety.
Post hoc analysis was 
change from baseline 
in TCS on DTT areas.
Least-squares mean 
change in TCS from 
baseline was signifi-
cantly greater for Cal/
BD foam (-5.8) than 
BV-medicated plaster 
(-3.7; difference 
-2.2; 95% confidence 
interval -2.6 to -1.8; 
p<0.001); greater 
changes for Cal/BD 
foam were observed 
from day 8 for each 
clinical sign. Absolute 
total skin and echo-
poor band thickness 
change was signifi-
cantly greater for Cal/
BD foam than for 
BV-medicated plaster 
(both p<0.001). Post 
hoc analyses showed 
that Cal/BD foam 
was significantly 
more effective than 
BV-medicated plaster 
on DTT areas after 4 
weeks (p<0.001).
Both treatments were 
well tolerated.
ACTH - Adrenocorticotropic hormone; ADRs – Adverse reactions; AEs – Adverse events; AUC – Area under the curve; DLQI - Dermatology Life-Quality Index; DTT 
– Difficult to treat; HR-QOL – Health-related quality of life; MDR - maximal dermal response; MCII - mean cumulative irritation index; mPASI – modified psoriasis 
area and severity index; pts – Patients; SAES – Serious adverse events; SD – Standard deviation; TCS - Total clinical score; y - Years
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difficult-to-treat areas) in patients with plaque psoriasis, a 
phase IIa (NCT02518048), randomized, single-centre, inves-
tigator-blinded, 4-week study was performed.31 Cal/BD foam 
and BV-medicated plaster were applied once daily to six test 
sites. Primary efficacy endpoint was absolute change in TCS; 
secondary endpoints were changes from baseline in each in-
dividual clinical score, ultrasonographic changes, and safety. 
Thirty-five patients were included. Least-squares mean chan-
ge in TCS from baseline was significantly greater for Cal/BD 
foam (-5.8) than BV-medicated plaster (-3.7; difference -2.2; 
95% CI -2.6 to -1.8; p < 0.001); greater changes for Cal/BD 
foam were observed from day 8 for each clinical sign. Absolu-
te total skin and echo-poor band thickness change was signifi-
cantly greater for Cal/BD foam than for BV-medicated plaster 
(p<0.001). Post hoc analyses showed that Cal/BD foam was 
significantly more effective than BV-medicated plaster on DTT 
(difficult-to-treat) areas after 4 weeks (p < 0.001) (Table 1).
3.1.3. Phase III
Cal/BD foam versus vehicle
The PSO-FAST (Psoriasis vulgaris, a Four-week, vehicle-
-controlled, efficacy And Safety Trial) study compared the 
Revista SPDV 76(1) 2018; New calcipotriol/betamethasone dipropionate foam formulation for the treatment of psoriasis; Tiago Torres, Paulo Filipe.
Table 1 (Cont.) - Efficacy and safety results from Cal/BD clinical trials. 
Clinical 
Trial
Study design Study population
Treatments & 
formulations
Endpoints/ 
Outcomes
Efficacy results Safety results
Phase III
Leonardi, 
201525
PSO-FAST
NCT01866163
Phase III, double-blind, 
randomized PSO-FAST 
(Cal/BD foam in 
PSOriasis vulgaris, a 
Four-week, vehicle-
controlled, efficacy And 
Safety Trial)
426 with ≥ mild severity 
psoriasis of the trunk 
and/or limbs from 27 
US outpatient sites.
426 patients were 
randomized (3:1) to 
Cal/BD foam or vehicle 
once-daily for 4 weeks 
(Cal/BD foam, N=323; 
vehicle, N=103).
Primary outcome: 
Proportion of patients at 
week 4 who achieved 
treatment success ac-
cording to physician's 
global assessment.
Secondary outcomes: 
Modified (excluding 
head) psoriasis area 
and severity index 
(mPASI) and patient's as-
sessment of itch (visual 
analogue scale). 
Safety was monitored by 
adverse events/calcium 
homeostasis.
At week 4, significantly 
more patients using 
Cal/BD foam achieved 
treatment success 
versus vehicle (53.3 vs 
4.8%; OR 30.3, 95% 
CI 9.7,94.3; p<0.001) 
and mean mPASI score 
was significantly lower 
for patients using Cal/
BD foam than vehicle 
(2.0 vs 5.5; adjusted dif-
ference -3.3, p<0.001). 
Significantly greater 
itch relief was observed 
for patients using Cal/
BD foam than vehicle 
(p=0.010 at day 3, 
p<0.001 from day 5).
Adverse drug reactions 
were reported in 10 
Cal/BD foam patients 
(3.1%) and two vehicle 
patients (1.9%); events 
occurred in one patient 
each except application 
site pain (Cal/BD foam, 
two patients; vehicle, 
one patient).
Cal/BD foam-related 
AEs: Discolouration, 
irritation, pruritus (all 
application-site events), 
application-site reaction, 
folliculitis, psoriasis, skin 
irritation and increased 
blood calcium (one pa-
tient each). Application-
site pain was reported 
by two patients.
Foam vehicle-related 
AEs: Application-site 
dryness, erosion, 
erythema and oedema, 
and application-site 
pain (one patient each).
AEs did not lead to 
treatment discontinu-
ations.
Two SAEs (single oc-
currences of bipolar 
disorder and substance-
induced psychotic dis-
order) were reported in 
Cal/BD foam recipients. 
Whether these events 
were treatment-related 
was not stated.
Leonardi, 
201641 
PSO-FAST 
HR-QOL
NCT01866163
426 patients with ≥ 
mild severity psoriasis 
of the trunk and/or 
limbs.
Patients were random-
ized (Cal/BD foam, 
N=323; vehicle, 
N=103).
Baseline mean DLQI 
scores were 9.9 (Cal/
BD foam) and 10.3 
(vehicle).
To compare the 
impact on HR-QOL 
of Cal/BD foam vs. 
vehicle in patients 
with mild-to-severe 
psoriasis.
HR-QoL was assessed 
by DLQI at baseline, 
weeks 1, 2, 4 and 
EQ-5D-5L at baseline 
and week 4 question-
naires. A DLQI score 
of 0 (range, 0-30) 
indicates no effect on 
the patient's life; an 
EQ-5D utility score 
of 1 (range, 0-1) 
and an EQ-5D visual 
analogue scale (VAS) 
score of 100 (range, 
1-100) indicate 
perfect health.
The impact of 
psoriasis on HR-QOL 
(EQ-5D utility score) 
at baseline was pri-
marily driven by pain/
discomfort (Cal/BD 
foam: 69.9%; vehicle: 
65.0%) and anxiety/
depression (Cal/BD 
foam: 45.3%; vehicle 
44.7%).
There was a greater 
improvement from 
baseline in DLQI score 
for Cal/BD foam vs 
vehicle at week 4 
(-7.0 vs -4.4; 
p<0.001); increased 
improvement was also 
seen in EQ-5D scores. 
At week 4, 48.1% of 
Cal/BD foam patients 
reported no effect of 
psoriasis on their lives 
(DLQI=0/1), and of 
patients using Cal/
BD foam with baseline 
DLQI scores ≥5, 
81.2% achieved a 
≥5-point improve-
ment.
ACTH - Adrenocorticotropic hormone; ADRs – Adverse reactions; AEs – Adverse events; AUC – Area under the curve; DLQI - Dermatology Life-Quality Index; DTT 
– Difficult to treat; HR-QOL – Health-related quality of life; MDR - maximal dermal response; MCII - mean cumulative irritation index; mPASI – modified psoriasis 
area and severity index; pts – Patients; SAES – Serious adverse events; SD – Standard deviation; TCS - Total clinical score; y - Years
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two-compound aerosol foam versus vehicle in a phase III 
(NCT01866163), multicentre, double-blinded, randomized, 
vehicle controlled, 4-week trial.25 From the 426 randomized 
patients, 53.3% achieved treatment success with Cal/BD foam 
versus 4.8% with vehicle only (p < 0.001). PASI score was 
lower in the combination group (2.0 vs 5.5, p < 0.001). At 
the end of the study, 82.3% of Cal/BD aerosol foam patients 
achieved at least a 50% reduction in mPASI (PASI50) compa-
red with 28.0% using vehicle (p < 0.001); 52.9% achieved 
at least a 75% reduction in mPASI (PASI75) compared with 
8.2% of vehicle patients (p < 0.001). Patients receiving Cal/
BD aerosol foam reported a rapid and significantly greater re-
duction in itch severity and improvement in itch-related sleep 
loss compared with vehicle, which was maintained throughout 
the study. These are very important findings because itch and 
itch-related sleep loss are common and distressing aspects of 
psoriasis that can aggravate the lesions and negatively impact 
patients’ daily productivity.34,32 Psoriasis’ impact on HR-QoL 
was also assessed. Baseline Dermatology Life-Quality Index 
(DLQI)33 for Cal/BD aerosol foam and vehicle groups were 
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Table 1 (Cont.) - Efficacy and safety results from Cal/BD clinical trials. 
Clinical 
Trial
Study design Study population
Treatments & 
formulations
Endpoints/ 
Outcomes
Efficacy results Safety results
Phase III
Paul, 201743
PSO-ABLE
NCT02132936
Randomized, parallel-
group, investigator-
blinded Phase III, 
12-week - PSO-ABLE 
study.
A total of 463 patients 
aged ≥18 years with 
mild-to-severe pso-
riasis were randomized 
4:4:1:1 to Cal/BD foam 
(n = 185), Cal/BD gel 
(n = 188), foam vehicle 
(n = 47), gel vehicle 
(n = 43)
Overall completion rate 
was 90%.
Patients were random-
ized to once-daily Cal/
BD foam, Cal/BD gel, 
foam vehicle or gel 
vehicle.
The primary efficacy 
endpoint was the pro-
portion of patients 
who were clear/almost 
clear with a ≥ 2 grade 
improvement according 
to the physician's global 
assessment of disease 
severity (i.e. treatment 
success) at week 4 for 
Cal/BD foam vs. week 8 
for Cal/BD gel.
Secondary efficacy 
endpoints included: 
proportion of patients 
achieving at least a 75% 
reduction in modified 
psoriasis area and 
severity index(mPASI75), 
and time to treatment 
success (TTTS). 
Safety was monitored 
throughout.
Cal/BD foam achieved 
higher treatment success 
rates (38% vs 22%; 
p<0.001) and mPASI75 
(52% vs 35%; p<0.001) 
by week 4 than Cal/BD 
gel by week 8. 
Median TTTS with Cal/
BD foam was 6 weeks; 
this could not be deter-
mined for Cal/BD gel as 
50% treatment success 
was not achieved 
(p<0.001). 
Adverse drug reactions 
were reported in 14 
(7.6%) Cal/BD aerosol 
foam patients and 7 
(3.7%) Cal/BD gel 
patients; all were single 
events except for itch 
with Cal/BD aerosol 
foam (n=5; 2.7%) and 
worsening psoriasis with 
Cal/BD gel 
(n=3; 1.6%).
No SAEs were reported.
Paul, 201744
PSO-ABLE Sub-
Group Analysis
NCT02132936
159 patients with 
moderate-to-severe 
psoriasis from the 
PSO-ABLE study.
Cal/BD foam and 
Cal/BD gel (77 and 
82 patients, respec-
tively).
To assess the response 
to Cal/BD foam and 
gel in patients with 
moderate-to-severe 
psoriasis enrolled in 
the phase III, 12-week 
PSO-ABLE study.
A greater proportion 
achieved mPASI75 
and mPASI90 with 
Cal/BD foam than gel 
at weeks 4, 8, and 
12 (57.1 vs 35.4%; 
p=0.006 and 15.6 
vs12.2% at week 12, 
respectively). The 
overall reduction in 
mPASI from baseline 
to week 12 was 64% 
with the foam vs 51% 
with the gel. Overall 
reduction in body 
surface area at week 
12 was 50% with the 
foam and 39% with 
the gel. Treatment suc-
cess rates were higher 
with the Cal/BD foam 
than the gel at weeks 
1, 2, 4, 8 (p=0.0089), 
and 12, and a greater 
proportion of foam 
patients achieved a 
DLQI score of 0/1 at 
weeks 4 (p=0.004), 8, 
and 12 (p=0.001).
ACTH - Adrenocorticotropic hormone; ADRs – Adverse reactions; AEs – Adverse events; AUC – Area under the curve; DLQI - Dermatology Life-Quality Index; DTT 
– Difficult to treat; HR-QOL – Health-related quality of life; MDR - maximal dermal response; MCII - mean cumulative irritation index; mPASI – modified psoriasis 
area and severity index; pts – Patients; SAES – Serious adverse events; SD – Standard deviation; TCS - Total clinical score; y - Years
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9.9 and 10.3, respectively, indicating a substantial impact on 
HR-QoL.25 Mean baseline EQ-5D utility index scores indicated 
that the impaired QoL in these patients was due to signifi-
cantly pain/discomfort and anxiety/depression compared with 
general population.25 A significant improvement in DLQI was 
observed with Cal/BD foam versus vehicle at week 4 (–7.0 vs 
–4.4; p < 0.001). Approximately 50% of Cal/BD foam pa-
tients reported that psoriasis had no effect on their lives at 
week 4 (DLQI score of 0 or 1) (Table 1).34
Cal/BD foam versus Cal/BD gel
The randomized, investigator-blinded, 12-week PSO-ABLE 
(Psoriasis - the effect of prolonged use of calcipotriol and beta-
methasone dipropionate combination therapy, a randomised, 
active- and vehicle-controlled 12-week trial) (NCT02132936) 
study34 compared Cal/BD aerosol foam with Cal/BD gel for 
4 and 8 week-treatment periods, respectively. Cal/BD foam 
achieved treatment success (38 vs 22%; p < 0.001) and 
mPASI75 (52 vs 35%; p < 0.001) in significantly more patients 
by week 4 than gel at week 8. Median time to achieve treat-
ment success with Cal/BD foam was 6 weeks, which could not 
be determined for Cal/BD gel as <50% of patients achieved 
treatment success (p < 0.001). Mean mPASI was significantly 
lower at week 4 for Cal/BD aerosol foam compared to gel at 
week 8 (2.2 vs 2.8; p = 0.028), and a significant difference 
was observed as early as week 1 (4.5 vs 5.2; p < 0.001). 
Regarding the impact on HR-QoL, DLQI scores improved by 
week 12 with both Cal/BD foam and gel. At weeks 4 and 12, 
significantly more patients using Cal/BD foam achieved DLQI 
scores of 0/1 than gel (week 4: 46% vs 32%, p = 0.013; week 
12: 61% vs 44%; p=0.03) (Table 1).
A sub-group analysis aiming to assess the response to 
Cal/BD foam and gel in patients with moderate-to-severe 
psoriasis from the PSO-ABLE study (77 and 82 patients, 
respectively)35 showed that a greater proportion of patients 
achieved mPASI75 and mPASI90 with foam than gel at weeks 
4, 8, and 12 (57.1 vs 35.4%; p = 0.006 and 15.6 vs 12.2% 
at week 12, respectively). The overall reduction in mPASI 
from baseline to week 12 was 64% with foam vs 51% with 
gel. Overall reduction in BSA at week 12 was 50% with Cal/
BD foam and 39% with gel. Treatment success rates were 
higher with Cal/BD foam than gel at weeks 1, 2, 4, 8 (p = 
0.0089), and 12, and a greater proportion of foam-trea-
ted patients achieved a DLQI score of 0/1 at weeks 4 (p = 
0.004), 8, and 12 (p = 0.001) (Table 1). This analysis came 
to prove that although moderate-to-severe psoriasis is typi-
cally treated with systemic/biologic therapies, Cal/BD foam 
is efficacious in these patients and may be a cost-saving al-
ternative to systemic therapy.44
3.2. Safety data
Safety profile of Cal/BD fixed combination is well esta-
blished. Although long-term continuous use of topical cor-
ticosteroids can lead to skin atrophy, recent studies have 
demonstrated that the addition of calcipotriol reduces the 
early signs of treatment-induced skin atrophy by modulating 
key extracellular matrix (ECM) components.2,13,36 Calcipotriol 
opposing effects on matrix metalloproteinases counteracts the 
betamethasone-induced suppression of collagen 1 and hya-
luronic acid synthesis.2,45 As local skin irritation calcipotriol-
-related are attenuated by betamethasone addition, most 
likely due to its anti-inflammatory properties, the fixed com-
bination has a more favourable tolerability profile compared 
with individual monotherapies.2,13,37  Moreover, the presen-
ce of calcipotriol may increase the effect of the steroid within 
the combination without affecting the tolerability profile.16,38 
Overall, adverse drug reactions were seen in 3.1% - 14% of 
patients regarding the two-compound treatment ointment or 
gel formulations.2 A long-term safety study of Cal/BD fixed 
combination for psoriasis’ treatment (a 52-week international, 
multicentre, randomized, double-blinded, long-term study) 
proved that the two-compound product has a safe and good 
tolerability profile.39
Clinical trials involving Cal/BD aerosol foam have de-
monstrated that this formulation is safe and well tolerated. 
Once that the application frequency is reduced by the com-
bination treatment foam, a significant reduction of both acti-
ve ingredients monotherapies-related adverse events (AEs) is 
also observed.13 AEs were generally of mild or moderate se-
verity,2,3,25,37- 39,43 mostly lesional or perilesional, rarely leading 
to treatment discontinuation.3,25,38,39 Skin atrophy, adrenal su-
ppression based on ACTH stimulating test, clinically relevant 
changes to HPA axis or calcium homeostasis were rarely re-
ported (Table 1).3,25,38,39,43
In a pooled safety analysis set including PSO-FAST pa-
tients25 and from two other trials of 4 weeks’ duration,38,39 (N 
= 1099) at least one treatment-related AE was reported in 
2.7% of Cal/BD foam recipients, 3.0% of Cal/BD ointment 
recipients, 6.1% of calcipotriol foam recipients and 7.1% of 
betamethasone foam recipients.3 In patients receiving Cal/BD 
foam, the most common treatment-related AEs (occurring in 
at least two patients) were application-site pruritus and pain 
(0.4% and 0.5%, respectively). Hypersensitivity (occurring in 
one patient) was the only serious AE that was considered pos-
sibly related to treatment. Two patients (0.4%) receiving Cal/
BD foam discontinued treatment because of AEs, but they 
were not reported as treatment-related.3
4. CONCLUSION
In recent years, clinical research has been focused on 
biologic or systemic treatment agents, which respond to the 
needs of a psoriatic patients’ minority (20%). Still, Cal/BD as-
sociation is the mainstay of treatment for mild-to-moderate 
psoriasis (80%). Ointment and gel formulations’ efficacy is 
well established in this population, however, many of these 
patizzents are not optimally controlled with available topical 
therapies and adherence to treatment remains a significant 
clinical challenge. Patients’ dissatisfaction regarding regimen 
inconvenience and treatment formulation, contributes to poor 
adherence to these therapies and lack of efficacy. As such, an 
effective, easy-to-use formulation should lead to an improved 
adherence in clinical practice.
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Cal/BD aerosol foam was developed to overcome these li-
mitations and to further increase patients’ therapeutic options. 
This alcohol-free foam, with a non-skin-drying emollient pa-
raffin-based vehicle, is applied once daily to the affected areas 
using a pressurized spray can, is rapidly effective for treating 
psoriasis, with a consistent and clinically relevant higher effi-
cacy than ointment and gel formulations. Enhanced efficacy 
is related to the improved skin penetration of the active ingre-
dients. Several studies have demonstrated that a stable super-
saturated solution of the active ingredients is formed when its 
solvent rapidly evaporates after application on the skin. This 
phenomenon increases the solubility of the active ingredients 
and leads to greater skin penetration and increased bioavaila-
bility, which in turn leads to greater efficacy of Cal/BD aerosol 
foam compared with other formulations. Clinical studies have 
showed growing patients’ satisfaction towards this optimized 
formulation, which has the potential for greater acceptability, 
leading to a higher adherence and treatment success than 
formulations that do not offer these characteristics, helping 
to address the unmet medical needs of patients with mild-to-
-moderate psoriasis.
Cal/BD aerosol foam formulation has proved a higher 
efficacy in clinical studies, without disregarding safety profile. 
A pooled analysis of the main clinical studies has demonstra-
ted that this greater efficacy does not occur at the expense of 
the safety profile. Phase II and III clinical trials have consisten-
tly shown the two-compound formulation to be more effective 
and safer than its individual ingredients in the same vehicle for 
treating body psoriasis. Furthermore, Cal/BD aerosol foam 
has shown a significantly improved efficacy compared with 
more traditional formulations, such as ointments, gels, and 
lotions.
Targeting specific molecules involved in the disease pa-
thophysiology, as observed in fixed-dose combination treat-
ment, results in an early and rapid response. This increases 
patients’ confidence in the treatment and adherence to it, 
which, in turn, contributes to a greater effectiveness. Research 
has shown that if patients believe a treatment is effective and 
easy to use they are more likely to be adherent, which similarly 
leads to better treatment’s outcomes. So, besides overcoming 
some of the limitations related with other topical treatments, 
Cal/BD foam is also a cost saving formulation. Once duration 
of therapy course is shorter and onset of action is faster, a re-
duced amount of Cal/BD foam would be required.
The PSO-ABLE study showed that >75% of patients felt 
that Cal/BD aerosol foam was more effective, easier to apply 
and more tolerable than other topical and systemic therapies 
they had previously experienced. One possible future initiative 
that could be considered is patient education regarding the 
importance of adherence to topical therapies. By combining 
appropriate patient education and the use of more effective 
topical therapies, it might be possible to control mild-to-mo-
derate psoriasis and avoid or delay systemic treatment intro-
duction.
As the aim of any pharmacological intervention is to indu-
ce disease remission and to prevent relapses, after achieving 
a free-disease state, its maintenance becomes the therapeutic 
goal. Inflammation tends to recur in previously affected lo-
cations, which may be caused by the expression and reac-
tivation of inflammatory cytokines present in the apparently 
normalized, plaque-free skin after treatment. Once that most 
topical therapies are approved for short-term use only (≤ 8 
weeks), there is a clinical need for a topical therapy that can 
be effectively used for long-term maintenance. Further clini-
cal investigations to explore the possibility of Cal/BD aerosol 
foam treatment ability to provide long-term psoriasis’ mana-
gement are required.
The improved efficacy and safety profile of the new formu-
lation of Cal/BD fixed-dose combination treatment, together 
with the once-daily treatment, a more acceptable tolerabili-
ty profile, and an early and rapid response, offers improved 
convenience and better acceptance over the twice-daily appli-
cations required for the respective monotherapies, which may 
improve adherence to treatment, and subsequently lead to 
faster and greater improvements in patients’ QoL, represen-
ting a useful therapeutic option to the management of patients 
with plaque psoriasis. 
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